US00461U1051 - Common Stock
ACLARIS THERAPEUTICS INC
NASDAQ:ACRS (4/25/2024, 7:00:00 PM)
After market: 1.22 +0.03 (+2.52%)1.19
+0.02 (+1.71%)
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 105 full-time employees. The company went IPO on 2015-10-07. The firm is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The firm has a multi-stage portfolio of drug candidates powered by a robust research and development (R&D) engine exploring protein kinase regulation. The firm operates through two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment includes provision of laboratory services. The firm is also engaged in identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.
ACLARIS THERAPEUTICS INC
701 Lee Road, Suite 103
Wayne PENNSYLVANIA 19087
P: 14843247933
CEO: Neal Walker
Employees: 105
Website: https://www.aclaristx.com/
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
/PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers...
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
HC Wainwright has downgraded Aclaris Therapeutics (ACRS) to neutral, citing underwhelming data from a Phase 2 study for its drug ATI-1777 in the treatment of at
Aclaris Therapeutics stock (ACRS) rises as the company begin a strategic review with a leadrship change as co-founder Neal Walker returns to CEO role. Read more here.
Here you can normally see the latest stock twits on ACRS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: